Ubs Asset Management Americas Inc Bei Gene, Ltd. Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 3,986 shares of BGNE stock, worth $903,666. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,986
Previous 3,336
19.48%
Holding current value
$903,666
Previous $616,000
46.59%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding BGNE
# of Institutions
295Shares Held
40.1MCall Options Held
111KPut Options Held
114K-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion23.78% of portfolio
-
Capital International Investors Los Angeles, CA5.09MShares$1.15 Billion0.24% of portfolio
-
Primecap Management CO Pasadena, CA5.06MShares$1.15 Billion0.97% of portfolio
-
Baillie Gifford & CO3.63MShares$823 Million0.74% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.71MShares$615 Million0.09% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...